Back to search
FDAFDA · Food and drugs·Recall number D-0515-2026

Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-099-03

Published May 13, 2026 · Recall initiated: April 29, 2026

Summary

FDA records drug Class II recall D-0515-2026, published May 13, 2026 and initiated April 29, 2026. Recalling firm: Ajanta Pharma Ltd.; Status: Ongoing; Reported quantity: 77,376 packs.; Lot: Lot#: PA07434, Exp. May 2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

What to do

Voluntary: Firm initiated · Letter

Get an email if DULOXETINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DULOXETINE
Manufacturer
Ajanta Pharma Ltd.
Distributor
Nationwide within U.S
UPC
0327241164309
Lot
Lot#: PA07434, Exp. May 2026.
Risk classification
Class II
Area (FDA)
drug
Country
India

Related recalls

Questions about this recall

Was Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-099-03 recalled?

Yes. FDA published recall D-0515-2026 on May 13, 2026. Reported hazard: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DULOXETINE. UPC: 0327241164309.